trial · primary record
Nivolumab
Hodgkin Lymphoma
| Phase | Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 37 |
| Primary completion | 2026-09-15 |
| Primary endpoint | Overall Response Rate (ORR) |
| Registry ID | NCT04981899 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:42:51.110Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04981899
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.